Matthew H. Taylor

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study”.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00241-2

N/A

5.2DataRank · unranked

186 citations

Amishi Y. Shah, Drew Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone +23 more

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2547

N/A

1.3DataRank · unranked

29 citations

Courtney B. Betts, Lauren Maloney, Eric Nadler, Alain P. Algazi, Michael J. Guarino +10 more

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Thyroid(2023)10.1089/thy.2023.0363

N/A

1.2DataRank · unranked

55 citations

Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor, Martin Schüler, Viola W. Zhu +19 more

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007929

N/A

0.783DataRank · unranked

19 citations

Matthew H. Taylor, Carol Aghajanian, Allen Lee Cohn, Marcia S. Brose, Christopher Di Simone +12 more

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

The Oncologist(2021)10.1002/onco.13883

N/A

0DataRank · unranked

34 citations

Matthew H. Taylor, Ana Oaknin, Antonio Casado, Robert Orlowski, Lea Dutta +4 more